[go: up one dir, main page]

CA3066077A1 - Inhibiteur d'agregation de tau - Google Patents

Inhibiteur d'agregation de tau Download PDF

Info

Publication number
CA3066077A1
CA3066077A1 CA3066077A CA3066077A CA3066077A1 CA 3066077 A1 CA3066077 A1 CA 3066077A1 CA 3066077 A CA3066077 A CA 3066077A CA 3066077 A CA3066077 A CA 3066077A CA 3066077 A1 CA3066077 A1 CA 3066077A1
Authority
CA
Canada
Prior art keywords
peptide
trp
absent
arg
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3066077A
Other languages
English (en)
Inventor
Shiho Tanaka
Ashley Wright
James Treanor
Marcin APOSTOL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADRx Inc
Original Assignee
ADRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADRx Inc filed Critical ADRx Inc
Publication of CA3066077A1 publication Critical patent/CA3066077A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne le domaine des inhibiteurs d'agrégation de tau. Plus particulièrement, l'invention concerne des agents thérapeutiques anti-amyloïdes. Plus précisément, l'invention concerne des compositions pharmaceutiques et des procédés de traitement d'états pathologiques ou maladies associés à une agrégation en utilisant certains peptides.
CA3066077A 2017-06-07 2018-06-07 Inhibiteur d'agregation de tau Abandoned CA3066077A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516393P 2017-06-07 2017-06-07
US62/516,393 2017-06-07
PCT/US2018/036507 WO2018226992A1 (fr) 2017-06-07 2018-06-07 Inhibiteur d'agrégation de tau

Publications (1)

Publication Number Publication Date
CA3066077A1 true CA3066077A1 (fr) 2018-12-13

Family

ID=62817070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3066077A Abandoned CA3066077A1 (fr) 2017-06-07 2018-06-07 Inhibiteur d'agregation de tau

Country Status (6)

Country Link
US (1) US20230137562A1 (fr)
EP (1) EP3634978A1 (fr)
JP (1) JP2020523035A (fr)
CN (1) CN110997693A (fr)
CA (1) CA3066077A1 (fr)
WO (1) WO2018226992A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106800590B (zh) * 2015-11-25 2021-04-09 杭州智鹤丹谷生物医药有限公司 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用
CA3100072A1 (fr) * 2018-05-15 2019-11-21 Interk Peptide Therapeutics Limited Agents d'activation
GB201820616D0 (en) * 2018-12-18 2019-01-30 Univ Of Lancaster Compositions for binding to tau proteins
EP3771719A1 (fr) * 2019-08-02 2021-02-03 Hochschule für angewandte Wissenschaften Fachhochschule Coburg Peptide se liant à la protéine tau
CN114057858B (zh) * 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
DE102020128632A1 (de) 2020-10-30 2022-05-05 Hochschule Für Angewandte Wissenschaften Coburg Tau-Protein-bindendes Peptid zur Therapie der Alzheimer-Demenz
KR102775835B1 (ko) * 2021-10-25 2025-03-06 한국과학기술연구원 알츠하이머병 모델 동물의 제조방법 및 그에 의해 제조된 알츠하이머병 모델 동물

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3343530A1 (de) 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
WO1987005330A1 (fr) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Procede pour ameliorer la stabilite des glycoproteines
US5078140A (en) 1986-05-08 1992-01-07 Kwoh Yik S Imaging device - aided robotic stereotaxis system
US5039794A (en) 1986-09-19 1991-08-13 Otsuka Pharmaceutical Co., Ltd. Tumor egress factor and processes for producing the same
EP0388434A4 (en) 1987-11-18 1990-12-19 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Differential delivery of therapeutic agents across the blood brain barrier
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
DK437289D0 (da) 1989-09-04 1989-09-04 Hans Bundgaard Prodrug derivatives of thyrotropin-releasing hormone (trh)
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
WO1991004014A1 (fr) 1989-09-21 1991-04-04 Synergen, Inc. Procede de transport de compositions a travers la barriere hemato-encephalique
JPH05500504A (ja) 1989-09-27 1993-02-04 アテナ・ニュウロサイエンスィズ・インコーポレイテッド 細胞付着阻止のための組成物及び使用方法
JPH03236315A (ja) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5270312A (en) 1990-11-05 1993-12-14 Warner-Lambert Company Substituted piperazines as central nervous system agents
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
RU2157239C2 (ru) 1992-07-13 2000-10-10 Юкэрион, Инк. Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
DK0614886T3 (da) 1992-07-30 1997-01-13 Drug Delivery System Inst Ltd Forbindelser, der kan tilbageholdes i hjernen
US5383988A (en) 1992-09-10 1995-01-24 Paragon Trade Brands, Inc. Modular apparatus for fabricating an absorbent article
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
EP0599303A3 (fr) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Conjugués peptidiques
EP0683234B2 (fr) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation
US5434137A (en) 1993-05-10 1995-07-18 Black; Keith L. Method for selective opening of abnormal brain tissue capillaries
AU7564194A (en) 1993-09-10 1995-03-27 University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
EP0952841A4 (fr) 1994-08-05 2000-11-02 Molecular Structural Biotechno Complexes biomoleculaires diriges
US5466683A (en) 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine
WO1996022303A1 (fr) 1995-01-16 1996-07-25 Commonwealth Scientific And Industrial Research Organisation Conjugues compose therapeutique - acide gras
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5865744A (en) 1996-09-16 1999-02-02 Lemelson; Jerome H. Method and system for delivering therapeutic agents
EP0957932A2 (fr) 1996-11-20 1999-11-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methode et composition permettant le passage a travers la barriere hemato-encephalique
ATE402717T1 (de) 1997-04-09 2008-08-15 Intellect Neurosciences Inc Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
EP1175210A4 (fr) 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc Renforcement de la biodisponibilite des medicaments dans le cerveau
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
KR100767146B1 (ko) 2000-02-24 2007-10-15 워싱톤 유니버시티 Aβ 펩티드를 격리시키는 인간화 항체
WO2001089583A2 (fr) 2000-05-23 2001-11-29 Neurologix, Inc. Systemes d'administration a base d'acide glutamique decarboxylase
AU3976402A (en) 2000-11-03 2002-06-03 Proteotech Inc Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
WO2003016466A2 (fr) 2001-08-17 2003-02-27 Eli Lilly And Company Anticorps anti-$g(a)$g(b)
FR2830016B1 (fr) 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DK2573170T3 (en) 2001-12-17 2018-04-09 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
CA2501945A1 (fr) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide beta-amyloide et compositions les comprenant
SI1583562T1 (sl) 2003-01-06 2011-10-28 Angiochem Inc AngioPep-1, sorodne spojine in njihove uporabe
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
MXPA05013770A (es) 2003-06-19 2006-03-08 Pfizer Prod Inc Antagonista de neuroquinina 1.
EP1666061A1 (fr) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Utilisation d'un anticorps
EP1720847A1 (fr) 2004-02-02 2006-11-15 Pfizer Products Incorporated Modulateurs du recepteur de l'histamine-3
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (fr) 2004-05-12 2005-11-16 Pfizer Limited Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine
KR101068289B1 (ko) 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
WO2006069081A2 (fr) 2004-12-22 2006-06-29 Washington University In St. Louis Utilisation d'anticorps anti-a$g(b) pour le traitement d'un traumatisme cerebral
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
ES2354569T3 (es) 2005-06-22 2011-03-16 Pfizer Products Inc. Antagonistas del receptor de histamina-3.
EP1857552A1 (fr) 2006-05-20 2007-11-21 Cargill Incorporated Xylose isomérase thermostable
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007063385A2 (fr) 2005-12-01 2007-06-07 Pfizer Products Inc. Antagonistes des recepteurs de l'histamine 3 pour des amines spirocycliques
WO2007069053A1 (fr) 2005-12-14 2007-06-21 Pfizer Products Inc. Antagonistes benzimidazoliques du récepteur h-3
CN102702044A (zh) 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
WO2007088450A2 (fr) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagoniste du récepteur h-3
WO2007088462A1 (fr) 2006-02-01 2007-08-09 Pfizer Products Inc. Antagonistes du récepteur du h-3 à base de spirochromane
PT1986661T (pt) 2006-02-08 2018-12-05 Genzyme Corp Terapia genética para a doença de niemann-pick tipo a
WO2007099423A1 (fr) 2006-03-02 2007-09-07 Pfizer Products Inc. Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3
CA2643055A1 (fr) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines en tant qu'antagonistes du recepteur h-3
EP2007795B1 (fr) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Protéines de capsides aav
WO2007138431A2 (fr) 2006-05-30 2007-12-06 Pfizer Products Inc. Antagonistes de l'éther histamine-3 azabicyclique
US8292769B2 (en) 2006-11-22 2012-10-23 Lawson Jr Thomas Towles Transmission
BRPI0806473A2 (pt) 2007-01-22 2011-09-27 Pfizer Prod Inc sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo
RU2009148866A (ru) 2007-06-01 2011-07-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
BRPI0814256A8 (pt) 2007-07-05 2016-02-10 Schering Corp Inibidores de tetrahidropiranocromeno gama secretase
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US20090238754A1 (en) 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry peptides across the blood brain barrier
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
AU2009314049B2 (en) 2008-11-13 2015-03-05 Merck Sharp & Dohme Corp. Gamma secretase modulators
SG10201502270TA (en) 2010-03-29 2015-05-28 Univ Pennsylvania Pharmacologically induced transgene ablation system
CA2833908C (fr) 2010-04-23 2021-02-09 University Of Massachusetts Vecteurs aav ciblant le systeme nerveux central et leurs procedes d'utilisation
MX336623B (es) 2010-06-14 2016-01-26 Hoffmann La Roche Peptidos penetradores de las celulas y usos de los mismos.
WO2011160126A2 (fr) * 2010-06-18 2011-12-22 Regents Of The University Of Colorado, A Body Corporate Riborégulateurs s-adénosyl-(l)-homocystéine (sah) et compositions et utilisations correspondantes
WO2012057363A1 (fr) 2010-10-27 2012-05-03 学校法人自治医科大学 Virions de virus adéno-associé pour le transfert de gènes dans des cellules neuronales
WO2012090150A2 (fr) 2010-12-27 2012-07-05 Compugen Ltd Nouveaux peptides pénétrant dans les cellules et leurs utilisations
WO2012115980A1 (fr) 2011-02-22 2012-08-30 California Institute Of Technology Fourniture de protéines au moyen de vecteurs de virus adéno-associés (aav)
US20130028956A1 (en) * 2011-07-29 2013-01-31 Andre Fischer Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore
CN104271147B (zh) 2011-12-27 2018-01-12 巴黎第六大学 细胞穿膜肽
MX2014014464A (es) 2012-06-26 2015-02-12 Hoffmann La Roche Peptidos penetrantes de celulas y metodos para identificar peptidos penetrantes de celulas.
JP2015523373A (ja) 2012-07-09 2015-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト eIF4Eを標的化するための細胞浸透性ペプチド
AU2013316679B2 (en) 2012-09-13 2017-12-14 Les Hopitaux Universitaires De Geneve Cell penetrating peptides
WO2014053882A1 (fr) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Peptides pénétrant dans les cellules pour l'administration intracellulaire de molécules
DE102012019882A1 (de) * 2012-10-05 2014-04-10 Forschungszentrum Jülich GmbH Peptide zur Behandlung und Frühdiagnose von Morbus Alzheimer und anderer Tauopathien
HK1211602A1 (en) 2012-10-08 2016-05-27 F. Hoffmann-La Roche Ag Cell penetrating peptides which bind irf5
EP2961757B1 (fr) 2013-02-28 2017-06-14 Oligomer Sciences AB Oligonucléotides pénétrant les cellules
WO2014147193A1 (fr) 2013-03-20 2014-09-25 Centre National De La Recherche Scientifique (Cnrs) Nouveaux motifs peptidiques pénétrant dans les cellules
AU2014265417B2 (en) 2013-05-15 2018-07-26 Regenxbio Inc. Adeno-associated virus mediated gene transfer to the central nervous system
CA2922516A1 (fr) * 2013-08-27 2015-03-19 The University Of British Columbia Peptides idr et anti-biofilm cationiques de petite taille
EP3044318B1 (fr) 2013-09-13 2019-05-01 California Institute of Technology Récupération sélective
WO2015075747A1 (fr) 2013-11-19 2015-05-28 Council Of Scientific And Industrial Research Peptide pénétrant les cellules pour la délivrance de molécules biologiques
HRP20211024T4 (hr) 2014-05-02 2025-06-20 Genzyme Corporation Aav vektori za gensku terapiju mrežnice i cns-a
JP6401871B2 (ja) 2014-11-05 2018-10-10 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. パーキンソン病の治療のためのaadcポリヌクレオチド
GB201421379D0 (en) 2014-12-02 2015-01-14 Isis Innovation Ltd And Medical Res Council Molecule
EP3237434A1 (fr) 2014-12-22 2017-11-01 F. Hoffmann-La Roche AG Peptides de pénétration cellulaire
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau

Also Published As

Publication number Publication date
EP3634978A1 (fr) 2020-04-15
US20230137562A1 (en) 2023-05-04
WO2018226992A1 (fr) 2018-12-13
WO2018226992A8 (fr) 2019-12-12
CN110997693A (zh) 2020-04-10
JP2020523035A (ja) 2020-08-06

Similar Documents

Publication Publication Date Title
US20230137562A1 (en) Tau aggregation inhibitors
US11453701B2 (en) Tau aggregation peptide inhibitors
US11753445B2 (en) Therapeutic peptides
JP6046493B2 (ja) プロミニン−1の血管新生促進フラグメントおよびその使用
CN114269367A (zh) 治疗性肽
US11117930B2 (en) Peptide inhibitors of transcription factor aggregation
CA3127336A1 (fr) Peptides therapeutiques
TW202204375A (zh) 治療冠狀病毒感染之方法
US20230372434A1 (en) Method of treating fibrosis with a combination therapy
WO2021030469A1 (fr) Peptides mitochondriaux thérapeutiques
HK40027708A (en) Tau aggregation inhibitors
US20240034753A1 (en) Therapeutic peptides
AU2019337806A1 (en) Peptides and medical uses thereof
HK40062304A (en) Therapeutic peptides
WO2021030752A1 (fr) Peptides thérapeutiques
WO2021030792A1 (fr) Peptides thérapeutiques
WO2021030749A1 (fr) Peptides thérapeutiques
WO2021030794A1 (fr) Peptides thérapeutiques

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20231207